Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy

References

• ParisiRSymmonsDPGriffithsCEAshcroftDMIdentification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project teamGlobal epidemiology of psoriasis: a systematic review of incidence and prevalenceJ Invest Dermatol20131332 377 38523014338
   PubMed Web of Science ®Google Scholar
• GordonKBStroberBEUnderstanding therapeutic pathways and comorbidities in psoriasisSemin Cutan Med Surg2014332 Suppl 2 S20 S2324979540
   PubMed Web of Science ®Google Scholar
• DavidoviciBBSattarNPrinzJPsoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditionsJ Invest Dermatol20101307 1785 179620445552
   PubMed Web of Science ®Google Scholar
• GottliebABDannFComorbidities in patients with psoriasisAm J Med200912212 1150.e1 e9
   Web of Science ®Google Scholar
• GisondiPFerrazziAGirolomoniGMetabolic comorbidities and psoriasisActa Dermatovenerol Croat2010184 297 30421251450
   PubMed Web of Science ®Google Scholar
• EspositoMSaracenoRGiuntaAMaccaroneMChimentiSAn Italian study on psoriasis and depressionDermatology20062122 123 12716484818
   PubMed Web of Science ®Google Scholar
• EspositoMFaleriSBabinoGFrom patients’ needs to treatment outcomes in psoriasis: results from the pSORRIDI experienceJ Int Med Res2016441 Suppl 95 9927683149
   PubMed Web of Science ®Google Scholar
• JacobsARosumeckSNastASystematic review on the maintenance of response during systemic antipsoriatic therapyBr J Dermatol20151734 910 92126280365
   PubMed Web of Science ®Google Scholar
• ParkHLiZYangXOA distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17Nat Immunol2005611 1133 114116200068
   PubMed Web of Science ®Google Scholar
• CaiYFlemingCYanJDermal γδ T cells–a new player in the pathogenesis of psoriasisInt Immunopharmacol2013163 388 39123499509
   PubMed Web of Science ®Google Scholar
• YaoZPainterSLFanslowWCHuman IL-17: a novel cytokine derived from T cellsJ Immunol199515512 5483 54867499828
   PubMed Web of Science ®Google Scholar
• GaffenSLJainRGargAVCuaDJThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testingNat Rev Immunol2014149 585 60025145755
   PubMed Web of Science ®Google Scholar
• GaffenSLThe role of interleukin-17 in the pathogenesis of rheumatoid arthritisCurr Rheumatol Rep2009115 365 37019772832
   PubMedGoogle Scholar
• KirkhamBWLassereMNEdmondsJPSynovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort)Arthritis Rheum2006544 1122 113116572447
   PubMed Web of Science ®Google Scholar
• KatzYNadivOBeerYInterleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukin 1, 6 and 8 in skin and synovial fibroblasts: a possible role as a “fine-tuning cytokine” in inflammation processArthritis Rheum2001449 2176 218411592383
   PubMed Web of Science ®Google Scholar
• ChabaudMFossiezFTaupinJLMiossecPEnhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokinesJ Immunol19981611 409 4149647250
   PubMed Web of Science ®Google Scholar
• JovanovicDVDi BattistaJAMartel-PelletierJIL-17 stimulates the production and expression of proinflammatory cytokines, IL-1beta and TNF alpha, by human macrophagesJ Immunol19981607 3513 35219531313
   PubMed Web of Science ®Google Scholar
• ChabaudMMiossecPThe combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo modelArthritis Rheum2001446 1293 130311407688
   PubMed Web of Science ®Google Scholar
• RuddyMJWongGCLiuXKFunctional cooperation between interleukin-17 and tumor necrosis factor-α is mediated by CCAAT/enhancer binding protein family membersJ Biol Chem20042794 2559 256714600152
   PubMed Web of Science ®Google Scholar
• LubbertsEIL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?Cytokine2008412 84 9118039580
   PubMed Web of Science ®Google Scholar
• BenderdourMTardifGPelletierJPInterleukin 17 (IL-17) induces collagenase-3 production in human osteoclastic chondrocytes via AP-1 dependent activation: differential activation of AP-1 members by IL-17 and IL-1betaJ Rheum20022921 1262 127212064845
   PubMed Web of Science ®Google Scholar
• KoshyPJHendersonNLoganCLifePFCawstonTERowanADInterleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokinesAnn Rheum Dis2002618 704 71312117676
   PubMed Web of Science ®Google Scholar
• ChiricozziAPathogenic role of IL-17 in psoriasis and psoriatic arthritisActas Dermosifiliogr2014105Suppl 1 9 2025398488
   PubMedGoogle Scholar
• LowesMARussellCBMartinDATowneJEKruegerJGThe IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responsesTrends Immunol2013344 174 18123291100
   PubMed Web of Science ®Google Scholar
• KruegerJGFretzinSSuárez-FariñasMIL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasisJ Allergy Clin Immunol20121301 145.e9 154.e922677045
   PubMed Web of Science ®Google Scholar
• JohansenCUsherPAKjellerupRBLundsgaardDIversenLKragballeKCharacterization of the interleukin-17 isoforms and receptors in lesional psoriatic skinBr J Dermatol20091602 319 32419016708
   PubMed Web of Science ®Google Scholar
• LowesMAKikuchiTFuentes-DuculanJPsoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cellsJ Invest Dermatol20081285 1207 121118200064
   PubMed Web of Science ®Google Scholar
• LiJChenXLiuZYueQLiuHExpression of Th17 cytokines in skin lesions of patients with psoriasisJ Huazhong Univ Sci Technolog Med Sci2007273 330 33217641855
   PubMedGoogle Scholar
• Guttman-YasskyELowesMAFuentes-DuculanJLow expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasisJ Immunol200818110 7420 742718981165
   PubMed Web of Science ®Google Scholar
• KagamiSRizzoHLLeeJJKoguchiYBlauveltACirculating Th17, Th22, and Th1 cells are increased in psoriasisJ Invest Dermatol20101305 1373 138320032993
   PubMed Web of Science ®Google Scholar
• CaproniMAntigaEMelaniLVolpiWDel BiancoEFabbriPSerum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trialJ Clin Immunol2009292 210 21418763027
   PubMed Web of Science ®Google Scholar
• LønnbergASZachariaeCSkovLTargeting of interleukin-17 in the treatment of psoriasisClin Cosmet Investig Dermatol20147 251 259
   PubMedGoogle Scholar
• RichPSigurgeirssonBThaciDSecukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding studyBr J Dermatol20131682 402 41123362969
   PubMed Web of Science ®Google Scholar
• RussellCBRandHBiglerJGene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibodyJ Immunol20141928 3828 383624646743
   PubMed Web of Science ®Google Scholar
• GenoveseMCVan den BoschFRobersonSALY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept studyArthritis Rheum2010624 929 93920131262
   PubMed Web of Science ®Google Scholar
• ChanACCarterPJTherapeutic antibodies for autoimmunity and inflammationNat Rev Immunol2010105 301 31620414204
   PubMed Web of Science ®Google Scholar
• LiuLLuJAllanBWGeneration and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin 17AJ Inflamm Res20169 39 5027143947
   PubMed Web of Science ®Google Scholar
• LeonardiCMathesonRZachariaeCAnti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasisN Engl J Med201236613 1190 119922455413
   PubMed Web of Science ®Google Scholar
• GordonKBLeonardiCLLebwohlMA 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasisJ Am Acad Dermatol2014716 1176 118225242558
   PubMed Web of Science ®Google Scholar
• GordonKBBlauveltAPappKAUNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study GroupPhase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasisN Engl J Med20163754 345 35627299809
   PubMed Web of Science ®Google Scholar
• ReichKLeonardiCLebwohlMSustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)J Dermatolog Treat2016 1 6
   Web of Science ®Google Scholar
• DennehyEBZhangLAmatoDGoldblumORichPIxekizumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: results from UNCOVER 3J Drugs Dermatol2016158 958 96127537996
   PubMed Web of Science ®Google Scholar
• van de KerkhofPGuentherLGottliebABIxekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3J Eur Acad Dermatol Venereol2017313 477 48227910156
   PubMed Web of Science ®Google Scholar
• ArmstrongAWLyndeCWMcBrideSREffect of Ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trialsJAMA Dermatol20161526 661 66926953848
   PubMed Web of Science ®Google Scholar
• SaekiHNakagawaHNakajoKJapanese Ixekizumab Study GroupEfficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J)J Dermatol2017444 355 36227726163
   PubMed Web of Science ®Google Scholar
• MeasePJvan der HeijdeDRitchlinCTSPIRIT-P1 Study GroupIxekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1Ann Rheum Dis2017761 79 8727553214
   PubMed Web of Science ®Google Scholar
• GriffithsCEReichKLebwohlMUNCOVER-2 and UNCOVER-3 investigatorsComparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsLancet20153869993 541 55126072109
   PubMed Web of Science ®Google Scholar
• BlauveltAPappKAGriffithsCEEfficacy and safety of switching to Ixekizumab in Etanercept non-responders: a subanalysis from two phase III randomized clinical trials in moderate-to-severe plaque psoriasis (UNCOVER-2 and -3)Am J Clin Dermatol2017182 273 28028074446
   PubMed Web of Science ®Google Scholar
• FarahnikBBeroukhimKZhuTHIxekizumab for the treatment of psoriasis: a review of phase III trialsDermatol Ther (Heidelb)201661 25 3726910853
   PubMed Web of Science ®Google Scholar
• GottliebABLacourJPKormanNTreatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studiesJ Eur Acad Dermatol Venereol Epub2016101
   Web of Science ®Google Scholar
• EspositoMGisondiPCassanoNSurvival rate of antitumor necrosis factor-a treatments for psoriasis in routine dermatological practice: a multicenter observational studyBr J Dermatol20131693 666 67223647206
   PubMed Web of Science ®Google Scholar
• Dyring-AndersenBSkovLZachariaeCIxekizumab for treatment of psoriasisExpert Rev Clin Immunol2015114 435 44225748485
   PubMed Web of Science ®Google Scholar
• ElyoussfiSThomasBJCiurtinCTailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesRheumatol Int2016365 603 61226892034
   PubMed Web of Science ®Google Scholar